29.50
+0.8(+2.79%)
Currency In USD
| Previous Close | 28.7 |
| Open | 29 |
| Day High | 30.12 |
| Day Low | 28.91 |
| 52-Week High | 42.27 |
| 52-Week Low | 6.43 |
| Volume | 413,623 |
| Average Volume | 635,322 |
| Market Cap | 1.08B |
| PE | -13 |
| EPS | -2.27 |
| Moving Average 50 Days | 26.89 |
| Moving Average 200 Days | 16.65 |
| Change | 0.8 |
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
GlobeNewswire Inc.
Dec 05, 2025 2:00 PM GMT
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’ disease severity RAP-219 demonstrated meaningful
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
GlobeNewswire Inc.
Nov 25, 2025 12:00 PM GMT
New analysis examines RAP-219’s effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across baseline disease severities, and impact on seizure severityBOSTON and SAN DIEGO, Nov. 25, 2025 (G
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
GlobeNewswire Inc.
Sep 11, 2025 8:05 PM GMT
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines